- Company
- Complaint against the plan to reduce benefits of α-GPC
- by Chon, Seung-Hyun Jun 30, 2020 06:11am
- Pharmaceutical companies agreed to file a complaint against the government's plan to reduce the reimbursement of Choline alfoscerate. It is suggested that the co-payment rate be lowered for reasons such as high cognitive impairment and brain-related diseases with high prescription rates. According to the industry on the 29th, more than 100 ex
- Policy
- Korea Passing Novartis Xolair listed for reimbursement
- by Kim, Jung-Ju Jun 30, 2020 06:10am
- The Korean health authority has decided to grant healthcare benefit from next month on Xolair (omalizumab), the controversial ‘Korea Passing’ drug that withdrew the reimbursement application amid the pricing negotiation to avoid lowering the global price, from next month. The listing of the novel severe asthma treatment Xolair took t
- Policy
- “KRW 10 bln COVID-19 vaccine budget plan unclear and vague"
- by Lee, Jeong-Hwan Jun 30, 2020 06:09am
- The voice of criticism is raised against weak and vague ‘budget plan on COVID-19 treatment and vaccine manufacturing facility establishment support (R&D)’ worth 10 billion won the Korean government included as a part of the third contingency budget plan. They point out a detailed business plan has to be set down first as the budget can be
- Company
- Spravato, a nasal spray for TRD entered the domestic market
- by Eo, Yun-Ho Jun 30, 2020 06:09am
- Spravato is the first nasal spray medication, taken along with an oral antidepressant, for adults with treatment-resistant depression (TRD) and it enters the domestic market. According to the related industry, Janssen’s Spravato nazal spray (Esketamine HCl) as a treatment for moderate to severe major depressive disorder (treatment-resist
- Policy
- Insurance benefits of Dupixent PFS 300mg will be possible
- by Lee, Hye-Kyung Jun 30, 2020 06:08am
- After the approval of the MFDS on April 1, insurance benefits of 'Dupixent PFS 300mg (dupilumab)' will be possible when the adolescent patients are over 18 years old. As a patient with chronic severe atopic dermatitis who is over 18 years of age and has symptoms that persist for more than 3 years, ▲ it is not adequately regulated even
- Company
- Prevymis by MSD is noted whether it is listed
- by Eo, Yun-Ho Jun 29, 2020 06:13am
- It is noteworthy whether the coverage for prevention of cytomegalovirus, infection in allogeneic hematopoietic stem cell transplant patients will be expanded. According to related industries, 'Prevymis (Letermovir)', a preventive treatment for cytomegalovirus (CMV) infection in allogeneic hematopoietic stem cell transplant patients, which
- Company
- Boycott Japan: Drug import rather increased in a year
- by Kim, Jin-Gu Jun 29, 2020 06:13am
- During a year of the Koreans boycotting against Japanese-made products, the total imported Japanese pharmaceutical sales have increased even more. But the trade balance has improved as the Korean-made pharmaceuticals exporting to Japan surged as well. Daily Pharm analyzed Korea Customs Service today and found the Japanese-made pharmaceutical
- Company
- Dong-A ST is first to evade antidiabetic Forxiga patent
- by Lee, Tak-Sun Jun 29, 2020 06:13am
- For the first time in Korea, Dong-A ST has successfully evaded pharmaceutical patent on sodium-glucose co-transporter-2 (SGLT-2) inhibiting antidiabetic treatment Forxiga (dapagliflozin) by AstraZeneca. According to the pharmaceutical industry on June 25, Dong-A ST’s request for the negative scope confirmation on two Forxiga patents was
- Policy
- α-GPC clinical reevaluation requires ₩50 billion
- by Lee, Tak-Sun Jun 29, 2020 06:13am
- The industry estimates the cost of clinical re-evaluation of the brain function improving agent 'Choline alfoscerate' to &8361;50 billion. This is the amount calculated when conducting clinical trials for all licensed indications. As the amount is large, the cost per company will be determined according to the number of companies participati
- Policy
- SNUH started a clinical trial of Remdesivir+Baricitinib
- by Lee, Jeong-Hwan Jun 29, 2020 06:12am
- Seoul National University Hospital announced on the 25th that it will be conducting a follow-up clinical trial of Remdesivir, which has proven effective as a treatment for COVID-19. This is a clinical trial that seeks drug efficacy and safety when Remdesivir is administered alone or when Baricitinib & Remdesivir are administered. Seou
